DR-131 The link between the immunologic and genomic characteristics of patients with metastatic melanoma and the possible effect on response to (immuno)therapy.

“Since almost 10 years, the outcome of patients with metastatic melanoma has improved significantly and long term durable responses have been realized. However, it remains difficult to predict which patient will benefit from therapy and besides that, severe adverse events occur in about 30-50% of the patients.
The aim of this project is to describe the genomic landscape of melanoma patients and to incorporate this into immunological and clinical analyses which we are currently performing. More insight into immunologic and genomic alterations in these patients could contribute to improved and more individualized therapeutic decision making.”

Astrid van der Veldt Erasmus MC The Netherlands